cancer or other proliferative diseases such conditions include but are not limited to viral infections such as herpesvirus poxvirus epstein barr virus sindbis virus and adenovirus autoimmune diseases such as systemic lupus erythematosus immune mediated glomerulonephritis rheumatoid arthritis psoriasis inflammatory bowel diseases and autoimmune diabetes mellitus neurodegenerative disorders such as alzheimer 39 s disease aids related dementia parkinson 39 s disease amyotrophic lateral sclerosis retinitis pigmentosa spinal muscular atrophy and cerebellar degeneration aids myelodysplastic syndromes aplastic anemia ischemic injury associated myocardial infarctions stroke and reperfusion injury restenosis arrhythmia atherosclerosis toxin induced or alcohol induced liver diseases hematological diseases such as chronic anemia and aplastic anemia degenerative diseases of the musculoskeletal system such as osteoporosis and arthritis aspirin sensitive rhinosinusitis cystic fibrosis multiple sclerosis kidney diseases and cancer pain the effective amount of the subject polymorphs particularly form a may be determined by one of ordinary skill in the art and includes exemplary dosage amounts for a human of from about 0 05 to 200 mg kg day which may be administered in a single dose or in the form of individual divided doses such as from 1 to 4 times per day preferably the subject polymorphs are administered in a dosage of less than 100 mg kg day in a single dose or in 2 to 4 divided doses it will be understood that the specific dose level and.